A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
NCT ID: NCT01287338
Last Updated: 2013-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
143 participants
INTERVENTIONAL
2010-10-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lower Puncta Delivery
Olopatadine
low dose
Double Puncta Delivery
Olopatadine
high dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olopatadine
low dose
Olopatadine
high dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin prick test to ragweed pollen within 12 months prior to visit 1
* BCVA of at leat 20/400
Exclusion Criteria
* Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires medical treatment
* Presence of follicular conjunctivitis, anterior uveitis or preauricular lymphadenopathy
* History of ophthalmic abnormality, including a history of dry eye
* Perennial allergic rhinoconjunctivitis having significant allergy to animal dander that cannot be avoided during the study period
* History of chronic bacterial or viral ocular infection, such as herpes keratitis, and/or presence of active bacterial or viral ocular infection
* presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular disease
* Currently on any chronic ocular topical medications
* Use of topical or systemic ocular medications during the study period
* History of complications, adverse events, trauma or disease in the nasolacrimal area
* History of symptomatic epiphoria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mati Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dipak Panigrahi, MD
Role: STUDY_DIRECTOR
QLT Inc.
Deepen Patel, MD
Role: PRINCIPAL_INVESTIGATOR
Cetero Research, San Antonio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cetero Research
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
141741
Identifier Type: OTHER
Identifier Source: secondary_id
PP0 AC 01
Identifier Type: -
Identifier Source: org_study_id